GobyMeds Semaglutide vs Tirzepatide: How Men Over 50 Should Choose

Disclosure: This post contains affiliate links. If you purchase through them, we may earn a commission at no extra cost to you. We only recommend products that meet our evidence standard.

If you’ve decided a GLP-1 is worth a conversation with a provider, the next question comes fast. Which one?

GobyMeds offers compounded versions of both. So the GobyMeds semaglutide vs tirzepatide decision isn’t really about the platform. It’s about the two molecules, what the research shows for each, and what you’re willing to pay and put up with. Here’s what the evidence says.

How Does Tirzepatide Work vs Semaglutide?

Semaglutide activates the GLP-1 receptor. Tirzepatide activates the GLP-1 receptor and the GIP receptor. That’s the whole mechanical difference.

The FDA label for Wegovy, the brand-name semaglutide for weight management, describes semaglutide as a GLP-1 analogue that acts on brain regions involved in food intake.

The Zepbound label, the brand-name tirzepatide, says the same about GLP-1 and adds that nonclinical studies suggest GIP “may further contribute to the regulation of food intake.” The second receptor is the leading explanation for the bigger average weight loss, not a proven one.

Is Zepbound the Same as Tirzepatide? What About Ozempic and Wegovy?

The active ingredient is the same. The brand name tells you what the FDA label covers.

Zepbound and Mounjaro are both tirzepatide. Wegovy and Ozempic are both semaglutide. The weight-management versions are Wegovy and Zepbound. Ozempic and Mounjaro are labeled for type 2 diabetes, and both labels also include a heart-risk indication for people with that diagnosis.

The Zepbound label lists two uses: reducing excess body weight and keeping it off long term, and treating moderate to severe obstructive sleep apnea in adults with obesity. The Wegovy label lists weight management, reducing the risk of heart attack, stroke and cardiovascular death in adults with established cardiovascular disease who also have obesity or overweight, and, for the injection, treating a type of liver disease called MASH with moderate to advanced scarring.

There’s a format difference, too. Wegovy comes as a once-weekly injection or as a daily tablet taken on an empty stomach with a 30-minute wait before eating. The Zepbound label lists injections only (pens, vials and KwikPens), once weekly.

Which Is Better for Weight Loss, Semaglutide or Tirzepatide?

On average, tirzepatide produced more weight loss in the trials. Both produced a lot.

The STEP 1 trial (NEJM, 2021) gave 1,961 adults without diabetes either semaglutide 2.4 mg weekly or placebo for 68 weeks, alongside a lifestyle program. The semaglutide group lost 14.9% of body weight on average. The placebo group lost 2.4%. About half the semaglutide group lost 15% or more.

The SURMOUNT-1 trial (NEJM, 2022) gave 2,539 adults without diabetes one of three tirzepatide doses or placebo for 72 weeks. Average weight loss was 15.0% on 5 mg, 19.5% on 10 mg and 20.9% on 15 mg, against 3.1% on placebo.

Those are separate trials, so they don’t compare the drugs directly. SURMOUNT-5 (NEJM, 2025) did. It put 751 adults with obesity on the highest dose each person tolerated of one drug or the other for 72 weeks. Tirzepatide averaged 20.2% weight loss. Semaglutide averaged 13.7%.

Two caveats. SURMOUNT-5 was open-label and funded by Eli Lilly, which makes tirzepatide. And all three trials tested the brand-name drugs, not compounded versions.

For a 220-pound man, 14.9% is about 33 pounds and 20.2% is about 44 pounds. Those are group averages, not a forecast.

Does Tirzepatide Have Fewer Side Effects Than Semaglutide?

Not clearly. Both labels list the same core problems: nausea, diarrhea, vomiting, constipation and stomach pain. In both trials, most of it was mild to moderate. In SURMOUNT-1 it came mainly while the dose was being raised; in STEP 1 it was typically short-lived and faded with time.

The label numbers look different on paper. In the Wegovy trials, 44% of patients reported nausea and 24% reported vomiting. In the Zepbound trials, nausea ran 25% to 29% and vomiting 8% to 13%, depending on dose.

Don’t read too much into that. Both labels warn that side effect rates from one drug’s trials can’t be directly compared to another drug’s trials. The ways people drop out tell a similar story. On the Wegovy label, 4.3% of patients stopped because of gut side effects, against 0.7% on placebo. On the Zepbound label it was 1.9% to 4.3% depending on dose, against 0.5%.

The serious warnings are shared too. Both labels carry a boxed warning about thyroid C-cell tumors seen in rodents, and both are off the table if you or a family member has had medullary thyroid carcinoma or MEN 2. Both list pancreatitis and gallbladder disease. Bring your full history to the intake. Our guide to GLP-1 side effects for men over 50 goes deeper on what to watch for.

Which Is Cheaper, Semaglutide or Tirzepatide? GobyMeds Pricing Compared

Semaglutide, at GobyMeds. As of October 26, 2026, first-time patients can start with a three-month bundle: $299 for compounded semaglutide or $399 for compounded tirzepatide, which works out to $99 and $133 a month. That’s about a $33 monthly gap on the starter bundles.

A single month is listed from $169 for semaglutide and from $299 for tirzepatide. After the starter, the three-month bundles are priced by the highest dose in your plan. GobyMeds lists three tiers for each drug, and at every tier the tirzepatide bundle costs $100 more than the semaglutide one.

GobyMeds says the starter bundles include medication, shipping, the consultation and an injection kit. Brand-name Zepbound is listed at $1,399 a month and Wegovy at $1,695 a month. There’s no subscription, and prescriptions are final sale. Confirm what your prescribed plan costs before you pay.

For comparison, NovoCare lists self-pay Wegovy pens at $349 a month for doses up to 2.4 mg. New patients pay $199 a month for the first two fills through December 31, 2026. Wegovy tablets run from $149 to $299 a month depending on dose, as read on October 26, 2026. Lilly lists its own Zepbound self-pay pricing on its savings page, so check that for the current figure before comparing.

One thing to be clear on. Compounded GLP-1s are not FDA-approved, and the FDA says salt forms such as semaglutide sodium and semaglutide acetate are different active ingredients from the ones in the approved drugs. Shipping, pharmacy and the rest of the fine print are covered in our GobyMeds review for men over 50.

What Happens If You Stop Semaglutide or Tirzepatide?

More than half of the lost weight came back, on both drugs.

In the STEP 1 extension (Diabetes, Obesity and Metabolism, 2022), 327 participants were followed for a year after treatment and lifestyle support stopped. They had lost an average of 17.3% of body weight on semaglutide. After a year off the drug, they regained 11.6 percentage points of it, leaving a net loss of 5.6%.

In SURMOUNT-4 (JAMA, 2024), 670 adults first took tirzepatide for 36 weeks and lost an average of 20.9%. Then half were switched to placebo. Over the next 52 weeks, the placebo group regained 14.0% of their week-36 body weight. The group that kept taking tirzepatide lost another 5.5%. At week 88, 89.5% of those still on tirzepatide had kept at least 80% of their weight loss, against 16.6% of those switched to placebo.

Both trials were funded by the drug makers, and SURMOUNT-4 averaged 48 years old and 71% women. If you start, ask your prescriber how long they expect you to stay on it and what the plan is when you stop.

Does Either Drug Lower Your Risk of a Heart Attack?

Semaglutide has the trial. Tirzepatide doesn’t have an equivalent for weight management on its label.

SELECT (NEJM, 2023) enrolled 17,604 adults aged 45 or older who had cardiovascular disease and a BMI of 27 or more but no diabetes. They took semaglutide 2.4 mg weekly or placebo, and were followed for a mean of about 40 months. A major cardiovascular event (cardiovascular death, nonfatal heart attack or nonfatal stroke) happened in 6.5% of the semaglutide group and 8.0% of the placebo group, a hazard ratio of 0.80. Novo Nordisk funded the trial. And 16.6% of the semaglutide group stopped the drug because of adverse events, against 8.2% on placebo.

That’s why the Wegovy label carries a heart indication and the Zepbound label doesn’t. If you already have heart disease, raise it with your cardiologist and your prescriber.

Should a Man Over 50 Take Semaglutide or Tirzepatide?

That’s a call for you and the prescriber. Here’s how I’d frame the conversation.

If the goal is the most weight loss the research supports, tirzepatide has the stronger head-to-head data. If you want the lower starting price, semaglutide makes a lot of sense. If you have established heart disease, semaglutide is the one with the outcomes trial behind it. If you have moderate to severe sleep apnea and obesity, tirzepatide’s label lists treating that.

Know who was in the trials, too. The Wegovy label reports a mean trial age of 48 and 71% women. The Zepbound pool averaged 47 years old and 37% men. The averages above weren’t built on men in their fifties and sixties, so treat them as a guide.

Whichever you pick, the dose schedule belongs to the prescriber. Both drugs start low and step up over months. Both labels also say not to use the drug with any other GLP-1 medicine, so this is an either-or choice, not a stack.

And after 50, the scale isn’t the only number that matters. Both labels say the drug takes off more fat than lean mass. That still means some of what you lose is lean mass. The medication makes eating less easier. Protein and strength training help decide how much of what you lose is fat. Our guide to GLP-1 for men over 50 covers who qualifies.

To get a provider’s opinion on which one fits your history, you can start a GobyMeds intake here.

Frequently Asked Questions

Is Zepbound the same as tirzepatide?

Zepbound is a brand name for tirzepatide, made by Eli Lilly and approved for weight management and for moderate to severe obstructive sleep apnea in adults with obesity. Mounjaro is the other brand name for tirzepatide, also made by Eli Lilly, and it is labeled for type 2 diabetes.

Is Ozempic the same as Wegovy?

Both contain semaglutide and both are made by Novo Nordisk. Ozempic is labeled for type 2 diabetes. Wegovy is labeled for weight management and for reducing cardiovascular risk in adults with established cardiovascular disease who also have obesity or overweight.

Can you take semaglutide and tirzepatide together?

Not recommended. The Zepbound label says using tirzepatide with any other GLP-1 receptor agonist is not recommended, and the Wegovy label says the same about using semaglutide with other semaglutide products or GLP-1 medicines.

Is compounded tirzepatide FDA-approved?

No. Compounded semaglutide and tirzepatide are not FDA-approved. GobyMeds says on its own site that its compounded medications have not been reviewed or approved by the FDA for safety or efficacy. The approved versions are the brand-name drugs.

How often do you take semaglutide and tirzepatide?

The Wegovy injection and Zepbound are both injected once a week. Wegovy also comes as a tablet taken once a day.

Related Reading

• Compounded vs brand-name GLP-1: every trial number in this post came from Wegovy and Zepbound, so read this before assuming a compounded dose behaves the same way.
• How to keep muscle on a GLP-1 after 50: a 20% drop in body weight only helps if most of it is fat, and this covers what the evidence says about keeping it that way.
• GobyMeds vs ShedRX: if the price gap between these two drugs is your sticking point, this lines up what the two telehealth services charge for each.